Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

Zentiva provides health and wellbeing for all generations, with focus on  developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond. Zentiva has four wholly-owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employes more than 5,000 unique talents, bonded together by a commitment to the people who depend on our medicines every day. Zentiva is private equity-owned, delivering sustainable growth, with an ambitious plan for the years to come.